
Dr. Reddy’s gets CDSCO nod for Zytorvi in esophageal cancer treatment
The story in brief
Dr. Reddy’s Laboratories has received CDSCO approval for Zytorvi in treating unresectable advanced, recurrent or metastatic ESCC. Esophageal cancer was the fourth leading cause of cancer-related death in India in 2024, with ESCC accounting for 80% of cases. The drug was launched in November 2024 for nasopharyngeal carcinoma, making India the third country to access it.